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ABSTRACT  
Objective. To determine the optimal patient-reported outcome measure 
(PROM) for assessing symptom benefit in trials of palliative chemotherapy for 
women with symptomatic ovarian cancer.   
Methods. Candidate PROMs were: EORTC QLQ-C30 plus ovarian-specific 
QLQ-OV28; Functional Assessment of Cancer Therapy-Ovarian (FACT-O); 
FACT-Ovarian Symptom Index (FOSI), gynecologic cancer-specific Symptom 
Representation Questionnaire (SRQ). Pre-defined optimality criteria were: 
inclusion of all symptoms necessary for the specified purpose; recall period 
covering typical length of palliative chemotherapy; numerical item rating 
scales; all necessary symptoms included in a single symptom index. 
Qualitative and quantitative methods were applied to data from Stage 1 of the 
Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) to 
determine the set of necessary symptoms, and to objectively assess 
candidate PROMs against the optimality criteria.  
Results. Ten necessary symptoms were identified: pain, fatigue, abdominal 
bloating/discomfort, sleep disturbance, bowel disturbance, nausea and 
vomiting, shortness of breath, poor appetite, urinary symptoms and weight 
changes. While QLQ-C30/OV28 together cover all these symptoms, they split 
them into numerous scales, dissipating potential symptom benefit signal.  
Conversely, FACT-O does not cover all necessary symptoms and contains 
many other HRQOL-related items and treatment side-effects, diluting potential 
symptom benefit signal when summed into scales. Item response scales and 
composite scoring of all candidate PROMs were suboptimal to our specific 
purpose. We therefore developed a new PROM, the Measure of Ovarian 
Symptoms and Treatment concerns (MOST), to provide optimal measurement 
for the specified purpose. 
Conclusions. This paper documents the development of the MOST, a new 
PROM designed to assess patient-reported benefits and burden as endpoints 
in clinical trials of palliative chemotherapy for women with symptomatic 
ovarian cancer. The validity, reliability and statistical efficiency of the MOST, 
relative to the best candidate scales of existing PROMs, will be assessed in 
Stage 2 of GCIG-SBS. 
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INTRODUCTION  
The primary objective of chemotherapy for women with symptomatic ovarian 
cancer is symptom control. The 3rd Ovarian Cancer Consensus meeting 
concluded that response rates and progression free interval were inadequate 
measures of the palliative benefit of chemotherapy and that symptom control 
and health-related quality of life (HRQoL) should also be considered as 
measures of treatment benefit [1].  This was endorsed by the 4th Ovarian 
Cancer Consensus meeting [2].  The Symptom Benefit working group was 
convened under the auspices of the Gynecologic Cancer Intergroup (GCIG), 
and the GCIG Symptom Benefit Study (SBS) (Clinical trial register - 
ACTRN12607000603415) was initiated after extensive consultation. 
The Symptom Benefit Study was designed in two stages. Stage 1 had two 
aims: 1) to describe and document the symptom burden, treatment and 
outcomes of women with platinum resistant/refractory recurrent ovarian 
cancer; 2) to determine the optimal instrument to measure subjective 
symptom benefit in clinical trials of palliative chemotherapy for ovarian cancer. 
The first aim is addressed in a companion paper [3]. We address the second 
aim, defining “optimal” as best able to provide efficient and focused 
measurement of symptom benefit for use in clinical trial endpoint analysis. 
HRQoL Questionnaires (MOVED HERE FROM METHODS, AND SHORTENED) 
Several patient-reported outcome measures (PROMs) have been designed to 
assess HRQoL in ovarian cancer [4]. The most widely used are the EORTC 
QLQ-OV28 [5], an ovarian-specific module used in conjunction with the core 
QLQ-C30 [6], and the FACT-O [7]. Since HRQoL is a multi-dimensional 
construct [4], these PROMs typically assess a range of issues, including 
various aspects of functioning and side effects of treatment, in addition to 
symptoms of ovarian cancer. Depending on the questionnaire’s scoring 
algorithm, symptoms may be split among various scales or combined with 
other aspects of HRQoL. How this is done and the implications for clinical trial 
endpoint analysis are explored in this paper.  
Symptom Indexes 
Symptom indexes are PROMs which provide a more focused approach, 
typically including only those symptoms that are most likely to be ameliorated 
by palliative treatment, with all symptoms summed into a single index [8]. Two 
symptom indexes have been developed specifically for ovarian cancer, the 
Ovarian Symptom Index (FOSI) [8, 9] and the NFOSI-18 [10], subsets of 8 
and 18 of the FACT-O items, respectively. The Symptom Representation 
questionnaire (SRQ), designed to assess the symptom experience of women 
with gynecologic cancers, also yields a composite index of symptom severity 
based on 22 items [11].   
The objectives of GCIG-SBS Stage 1 addressed in this paper are: 
1) to evaluate existing PROMs (QLQ-C30/OV28, FACT-O, FOSI-8, 
NFOSI-18 and SRQ) in terms of their optimality as measures of 
symptom benefit for use in endpoint analysis of clinical trials of 
palliative chemotherapy for ovarian cancer; and 
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2) if existing PROMs are found to be suboptimal in regard to 1), to 
develop a PROM optimally designed for that purpose.   
METHODS 
Participants and study procedures are described in detail in the companion 
paper [3]. The key points for this paper are: 1) patients with platinum 
resistant/refractory recurrent ovarian cancer self-completed a HRQoL booklet 
before starting palliative chemotherapy (baseline); and 2) a subset of patients 
completed a structured interview.  
Patient-reported outcome measures 
The HRQoL booklet included seven validated PROMs, in this order: Symptom 
Representation Questionnaire [11], FACT-O v4 [7], QLQ-C30 v3 [6], QLQ-
OV28 [5], Patient Disease and Treatment Assessment Form (Pt DATA Form) 
[12]; Hospital Anxiety and Depression Scale (HADS) [13]; and Herth Hope 
Index (HHI) [14]. This paper utilizes baseline data from SRQ, QLQ-C30/OV28, 
and FACT-O/FOSI; data from the other timepoints and questionnaires are 
reported separately [3, 15].  
Optimality criteria [NEW SECTION] 
To determine the optimal PROM to measure subjective symptom benefit in 
clinical trials of palliative chemotherapy for ovarian cancer, we first defined 
“optimal” as best able to provide efficient and focused measurement of 
symptom benefit for use in clinical trial endpoint analysis. We operationalized 
this definition in terms of four optimality criteria derived from key elements of 
the first two steps of the process for developing a PRO instrument for use in 
clinical trials recommended by the Food and Drug Administration (FDA) [16]: 
1) content validity: in this context, defined as: symptoms necessary and 
sufficient for the target population (women with symptomatic ovarian cancer) 
and purpose (to provide efficient and targeted measurement of symptom 
benefit for use in clinical trial endpoint analysis). The guiding principle was 
“everything that matters and no more”, so items that were not necessary to 
this purpose were considered surplus to it; 
2) recall period: should be long enough to capture all effects within a cycle of 
palliative chemotherapy, i.e. 3-4 weeks;  
3) numerical rating scale for items: a systematic review has established that 
numerical rating scales have better responsiveness and ease of use and 
higher compliance rates relative to visual analogue or verbal rating scales 
[17];  
4) symptom index scoring: whereby all necessary symptoms are summed into 
a single index, providing a statistically efficient trial endpoint [18].   
As per the FDA’s PRO guidance [16], qualitative and quantitative methods 
were used to objectively assess the optimality criteria. 
Qualitative analysis 
Structured interviews were conducted in a subsample (n=20) to assess 
patients’ opinions about the completeness of coverage of issues in the 
HRQoL booklet, and importantly, whether any issues had been left out 
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(Criterion 1). Patients’ preference for existing questionnaires and response 
formats were also elicited. Eligible patients: 1) were symptomatic at baseline; 
2) completed ≥3 cycles of chemotherapy; 3) completed the HRQoL booklet 
prior to each cycle of chemotherapy. We sampled purposively to obtain a 
balanced mix of patients whose symptoms improved, persisted or worsened 
from baseline to their last HRQoL assessment, and until data saturation was 
achieved. Selected patients were invited to participate by their research 
nurse. An independent, professional interviewer then arranged a telephone 
interview with the participant, which was audiotaped. Participants received a 
summary of their HRQoL responses by post for reference during the 
interview. Transcribed interviews were content-analysed for reports of 
additional symptoms not covered in the HRQoL booklet, and patients’ 
opinions about the comprehensiveness of coverage of relevant issues by the 
questionnaires, the ease of use of item response scales, and their preference 
among the questionnaires.   
Quantitative Analysis 
The purpose of the quantitative analysis was to determine which symptoms 
were necessary and sufficient for the target population and purpose (i.e. to 
specify the symptom set for Criterion 1). The SRQ was the ideal measure for 
this purpose, as it contains a comprehensive set of symptoms, allows patients 
to nominate a further three symptoms, and asks which three symptoms the 
patient has “noticed most in the last week” (referred to hereafter as the “Top 
3”). We assessed two aspects of the SRQ data. First, symptoms that were 
noticed most across the sample were determined by calculating the frequency 
of each symptom nominated in the “Top 3” (including the three optional 
additional symptoms). We set a threshold of 5% as we judged this to be 
sufficiently common to warrant inclusion as an item in a symptom index, and 
that lower prevalence would add respondent burden for very little information 
gain.  Second, the most prevalent or severe symptoms were determined by 
calculating the mean and standard deviation of ratings of all 22 symptoms 
listed on the SRQ. Analyses were conducted using SAS software, version 9.2 
(SAS Institute).  
Assessment of existing PROMs 
The QLQ-C30/-OV28, FACT-O, FOSI and SRQ were assessed against the 
optimality criteria by considering item content (Criterion 1), recall period 
(Criterion 2), item response scale (Criterion 3) and scoring algorithm (Criterion 
4).  
[Development of the MOST – MOVED DOWN, CONSOLIDATED UNDER SAME HEADING 
IN RESULTS] 
 
RESULTS 
Participants 
126 women participated in Stage 1 of GCIG-SBS, 124 completed baseline 
HRQoL booklets and 123 had at least 1 cycle of chemotherapy. Patient 
characteristics and details of their symptom experience at baseline are given 
in the companion paper [3].  Thirty women were approached for interviews, 
eight declined and 22 were interviewed, at which point data saturation had 
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been achieved. Two interviews were excluded due to poor quality audio 
recording. The 20 women included in the qualitative analysis ranged in age 
from 48 to 86 years (mean 65.5). At the time of interview: three participants 
had completed three cycles of chemotherapy, 13 had completed four cycles 
and four had completed five cycles; 10 reported at least two baseline 
symptom had improved by 2 or more points, three reported worsening by 2 or 
more points of at least two baseline symptoms, and seven remained stable. 
Establishing the symptom set for content validity [AMENDED HEADING, 
PREVIOUSLY “Patients Top 3 Symptoms and coverage by PROMS”] 
Interviewees generally agreed that all pertinent issues were covered in the 
HRQoL booklet, and none believed important issues were absent. Some 
participants did not complete the FACT-O sexuality items, stating that they 
were “intrusive” and not relevant. [THIS PARAGRAH MOVED UP, PREVIOUSLY 
UNDER HEADING “PATIENT INTERVIEWS”, NOW REMOVED] 
Table 1 summarises the 10 symptoms nominated by at least 5% of our 
sample as in the Top 3 symptoms are shown in Table 1, along with the mean 
(SD) rating. Items that were more frequently nominated in the Top 3 also 
tended to have higher severity ratings. On this basis, we considered these 10 
symptoms necessary and sufficient to measure subjective symptom benefit in 
clinical trials of palliative chemotherapy for ovarian cancer, thereby 
establishing symptom set for Criterion 1.  
Assessment of PROMs against the optimality criteria 
Table 2 summarises the extent to which each of the candidate PROMs 
addresses the measurement optimality criteria. Table 3-5 provide further 
detail for Criteria 1 and 4.  
Criteria1 and 4: content validity and item-into-scale aggregation 
Table 3 summarises the number of items in QLQ-C30/OV28, FACT-O, FOSI-
8 and NFOSI-18 that address the 10 necessary symptoms, and the number of 
items addressing other issues (“surplus items” for brevity).  
Together, the QLQ-C30 and QLQ-OV28 cover all 10 necessary symptoms 
with a total of 20 items. The EORTC scoring algorithm integrates these 20 
items into 10 separate summary scales, with a further 13 scales scored from 
the 38 surplus items (Table 4).  
The FACT-O covers 8 of the 10 necessary symptoms with 10 items, asking a 
further 29 surplus items. The FACT-O scoring algorithm integrates the 10 
necessary items into 8 non-independent summary scales (i.e. each item 
contributes to several scales) (Table 5). The scale with the highest ratio of 
necessary to surplus items is the trial outcomes index (TOI), containing all 10 
necessary items plus 16 surplus items. 
The FOSI-8 covers only 4 of the 10 necessary symptoms with 6 items, and 
the NFOSI-18 covers a further 2 of the 10 necessary symptoms (still missing 
4), plus a further 8 surplus items (Table 5). The 9-item Disease-Related 
Symptoms – Physical (DSR-P) subscale of the NFOSI-18 contains the highest 
ratio of necessary to surplus items, containing 8 necessary items plus “I feel 
ill”. 
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The SRQ contains all 10 necessary items, along with 12 others, and includes 
all 22 in a composite symptom index.  
 
Criterion 2: Recall period  
The recall period for all the existing PROMs is the past week.  
Criterion 3: Item response scales 
The EORTC and FACIT questionnaires use similar 4-point and 5-point verbal 
rating scales, respectively, while the SRQ uses an 11-point numeric rating 
scale. The verbal anchors for all these rating scales are described in the 
footnotes to Table 2. 
Patients’ preferences for existing PROMs 
Overall, interviewees did not express consistent preferences between existing 
HRQoL questionnaires regarding they content or item response format; 17/20 
did not have a preferred questionnaire, the SRQ and Patient DATA Form 
were preferred by one participant each, and one participant was not asked the 
question. Five participants preferred the EORTC 0-4 response format, three 
preferred the 0-10 format of the SRQ and Patient DATA Form, one participant 
preferred the EORTC Global QoL 0-7 format, one was not asked the question 
and the remaining 10 did not have a preference.  
Participants explained the importance of presenting questions simply. Many 
participants found it difficult to complete questionnaires where the direction of 
coding was switched (i.e. FACT-O/FOSI).  Some participants commented that 
a week was too short for the recall period.  
The MOST (Measure of Ovarian Cancer Symptoms and Treatment 
Concerns) 
Since none of the candidate PROMs met all the optimality criteria, we 
designed a new measure, the MOST, to meet all our optimality criteria, and 
taking into consideration patients’ qualitative feedback. We adapted the 
Patient DATA form [12] for this purpose, adding the additional necessary 
symptoms. Following the FDA’s PRO Guidance, we specified a conceptual 
framework that included two key concepts: symptom benefit and treatment 
burden. To address the latter, we included a comprehensive selection of 
chemotherapy side-effects, based on the items in the Treatment Concerns 
section of the Patient DATA Form [12].  
The MOST contains 35 items (Figure 1): 15 assess disease symptoms, 17 
assess adverse effects of treatment (“treatment concerns”), and 3 assess 
wellbeing (physical, emotional, overall). The wording and layout are simple, 
like that of the SRQ and Patient DATA Form. 
The MOST has two forms, the main one being the recent status form, which 
aims to determine how troublesome various disease symptoms and treatment 
problems have been in the period between chemotherapy cycles; thus 
respondents are asked “how much that aspect troubled you on average 
during the last 3-4 weeks”. This from is designed to be completed when 
patients attend for clinical assessment prior to their next cycle of 
chemotherapy. The 32 symptoms are rated on an 11-point numeric rating 
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scale, from 0 = “no trouble at all” to 10 = “worst I can imagine”, with 
intermediate verbal anchors at 2 = “mild”, 5 = “moderate” and 8 = “severe”. 
The three wellbeing items range from 0 = “worst possible” to 10 = “best 
possible”.  The MOST change form contains the same items, but asks 
patients to report their perceived change since “before you started this course 
of chemotherapy 6-8 weeks ago”. This form is designed to allow estimation of 
the minimally important difference [19, 20], which will be done in Stage 2 of 
GCIG-SBS.  
DISCUSSION  
Our analysis of data from Stage 1 of GCIG-SBS showed that the disease-
related physical symptoms that were most noticed and most severe in this 
sample of women with platinum resistant/refractory recurrent ovarian cancer 
were pain, fatigue, abdominal bloating and discomfort, sleep disturbance, 
bowel problems, nausea and vomiting, shortness of breath, poor appetite, 
urinary symptoms and weight changes. Emotional problems were also 
commonly noticed and relatively severe, as were two treatment related 
symptoms (hot flushes, numbness and tingling). Our analysis of the content of 
existing ovarian-specific HRQOL questionnaires revealed that while the 
EORTC QLQ-C30 and QLQ-OV28 together cover all of these symptoms, their 
mandated scoring algorithms dissipate the impact of these symptoms by 
splitting them into numerous scales.  The FACT-O covered all but two of the 
necessary symptoms, but also included many other HRQoL-related issues, 
leading to dilution in multi-item summary scales. The latter shortcoming has 
been recognized and addressed to some extent in the development of the two 
FACIT Ovarian Symptom Indexes [8-10].  However our analysis shows that 
even these are somewhat diluted by other issues. The scales that are most 
focused are the EORTC abdominal/gastrointestinal scale, FACT-O TOI, and 
FOSI-18 DSR-P.  
This paper documents the preliminary development of the MOST, a new 
PROM designed to assess patient-reported benefits and burden as endpoints 
in clinical trials of palliative chemotherapy for women with symptomatic 
ovarian cancer. We used qualitative and quantitative methods to identify 
symptoms relevant to this patient population and clinical context, as 
recommended by the FDA for the development of PROMs for clinical trials 
[16] and for comparative effectiveness research [21]. We note that the MOST 
includes the 12 core symptoms recommended for consideration in studies in 
advanced or metastatic cancers [21]. Our choice of a numerical rating scale 
for the MOST items is supported by a systematic review showing that such 
scales have better responsiveness and ease of use and higher compliance 
rates relative to visual analogue or verbal rating scales [17]. Our work to this 
point, based on Stage 1 of the GCIG-SBS, covers Steps 1 and 2 of the 
iterative process recommended by the FDA for developing a PRO instrument 
for use in clinical trials (Figure 3, page 7) [16]. We will complete this iterative 
process, covering Steps 3-5 in Stage 2 of GCIG-SBS. This will include 
determining the scoring algorithm, psychometric properties, and interpretation 
guidelines (including the minimally important difference) for the MOST. 
Consistent with our conceptual framework, we envisage a scoring algorithm 
yielding one symptom index and one treatment problems index, such that the 
benefits and burden of chemotherapy can be quantified independently and 
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precisely in any given trial. Previous studies have confirmed that major gains 
in measurement precision can be achieved by including a relatively large 
number of items in a summary scale [18].   
The MOST may also have broad clinical utility, with potential to enhance 
communication between patients and clinicians about symptom benefit and 
treatment burden and inform shared decision-making about whether or when 
to stop chemotherapy [22]. Using MOST in clinics would probably enable 
clinicians to better understand and treat the symptoms that matter most to 
these patients. 
Arguably, the QLQ-C30/OV28, FACT-O and FOSI are currently the best 
available PROMs for ovarian cancer. Some of their scales are sensitive to 
differences in performance status, relapse versus no relapse, survivors versus 
general population, and chemotherapy naïve versus known neuropathy [4]. All 
six randomized controlled trials of chemotherapy in the platinum 
resistant/refractory recurrent ovarian cancer population that have assessed 
HRQoL have used QLQ-C30, FACT-O or FOSI [23, 24]. Yet only one has 
demonstrated changes over time in PROs [25], and none has demonstrated a 
difference in PROs between trial arms. We have developed the MOST as a 
complement, not a substitute, for these PROMs, with the aim of providing 
optimal assessment of subjective symptom benefit in future trials. A thorough 
validation of the MOST will be undertaken as part of Stage 2 of GCIG-SBS. 
Data are currently being collected in Australia, Canada, Denmark, England, 
France, Germany, Italy, Ireland, Japan, Sweden, and the United States of 
America. The QLQ-C30/OV28, FACT-O and FOSI are being used, alongside 
the MOST, in order to assess the MOST’s measurement properties relative to 
those PROMs, in particular, responsiveness to clinically important change and 
relative statistical efficiency [18].  We will focus our comparisons on the scales 
that best target symptoms of ovarian cancer, i.e. QLQ-OV28 
abdominal/gastrointestinal scale, FACT-O TOI, FOSI-18 DSR-P. If found to be 
valid, reliable and responsive, the MOST will be an excellent candidate PROM 
for clinical trials of ovarian cancer where the objective of treatment is 
symptom improvement.  
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Figure and Table Legends 
Figure 1: The Measure of Ovarian Symptoms and Treatment concerns 
(MOST) 
Table 1:  Symptoms nominated most often by the patients in their “Top 3” 
symptomsa in the Symptom Representation Questionnaire (SRQ) at baseline, 
number (%) of patients who nominated each, and mean (SD) rating of each 
symptom at its worst (N = 124) 
Table 2: Summary of the extent to which the existing candidate patient-
reported outcome measures and the new questionnaire (MOST) met the 
optimality criteria for efficient  and focused measurement of symptom benefit 
for clinical trial endpoint analysis. 
Table 3:  Number of questions in the QLQ-C30, QLQ-OV28, FACT-O and 
FOSI (8 and 18 item versions) that address the 10 symptoms that are 
necessary to measure subjective symptom benefit in clinical trials of palliative 
chemotherapy for ovarian cancer, and number that address other issues 
(surplus items). 
Table 4:  Number of summary scales in the QLQ-C30 and QLQ-OV28, and 
the number of questions in each that address the 10 symptoms necessary to 
measure subjective symptom benefit in clinical trials of palliative 
chemotherapy for ovarian cancer. 
Table 5: Number of multi-item scales in the FACT-G, FACT-O and FOSI (8 
and 18 item versions), and the number of items in each that address the 10 
symptoms necessary and sufficient to measure subjective symptom benefit in 
clinical trials of palliative chemotherapy for ovarian cancer.   
 
Table 1  Symptoms nominated most often by the patients in their “Top 3” symptomsa 
in the Symptom Representation Questionnaire (SRQ) at baseline, number (%) of 
patients who nominated each, and mean (SD) rating of each symptom at its worst (N 
= 124) 
 
“Top 3” Symptomsa No. of patients % Meanb (SD) 
Pain 55 44 3.7 (3.1) 
Fatigue 46 37 4.2 (2.8) 
Abdominal bloating/discomfort 39 32 3.6 (3.2) 
Sleep disturbance 30 24 3.6 (3.1)  
Bowel problems 27 22 3.7 (3.4) 
Nausea/vomiting 24 19 2.1 (2.6) Nausea 
1.1 (2.4) Vomiting 
Emotional 20 16 2.5 (2.6) Depression 
   1.9 (2.2) Mood swings 
(Numbness/tingling) 13 11 1.6 (2.3) 
Shortness of breath 13 11 2.0 (2.5) 
Poor Appetite 12 10 2.7 (2.9) 
(Hot flushes) 11 9 1.6 (2.4) 
Urinary problems 9 7 1.4 (2.5) 
Weight changes 7 6 1.2 (2.2) Weight loss 
   0.9 (2.3) Weight gain 
Miscellaneous: 14c 11  
a Patients first rated each of 22 specific symptoms (2 “other” unspecified symptoms could 
also be nominated and rated), then listed “the 3 symptoms that you noticed most in the 
last week”, which we refer to as the “Top 3”. Parentheses denote two symptoms which 
are likely to be long-term side-effects of previous course of chemotherapy. 
b Each symptom was rated “at its worst in the past week” on an 11-point scale, where 0 
= “did not have the symptom” to 10 = “as bad as I can imagine”. 
c 14 patients listed 15 other symptoms: leg cramping/cramping (unspecified), 
alopecia, cough, thirst, sexual problems, high pressure originating in my chest then 
neck, face sweeling, feet blisters, swollen leg, ringing in ear, fever 
Table 2 Summary of the extent to which the existing candidate patient-reported outcome measures and the new questionnaire (MOST) met the 
optimality criteria for efficient  and focused measurement of symptom benefit for clinical trial endpoint analysis.  
Optimality Criteria QLQ-C30/OV28 FACT-O FOSI-8 FOSI-18 SRQ MOST 
1. content validity1 Met: all 10 
necessary 
symptoms, plus  38 
surplus items 
Partially met:  
8/10 necessary 
symptoms, plus  
29 surplus items 
Partially met: 
6/10 necessary 
symptoms, 
and 2 surplus 
items 
Met: all 10 necessary 
symptoms, and 8 
surplus items 
Met: all 10 
necessary 
symptoms, 
plus  12 
surplus items 
Met: all 10 necessary 
symptoms, plus  20 
surplus items 
2. Recall period of 
3-4 weeks2  
Not met:  
recall of 1 week 
Not met:  
recall of 1 week 
Not met: 
recall of 1 
week 
Not met: recall of 1 
week 
Not met: 
recall of 1 
week 
Met 
3. Numerical rating 
scales for item 
responses 
Not met:  
4-point verbal 
rating scale3a 
Not met:  
5-point verbal 
rating scale3b 
Not met:  
5-point verbal 
rating scale 
Not met:  
5-point verbal rating 
scale 
Met: 0-10 
numeric 
rating scale3c 
Met: 0-10 numeric 
rating scale3d 
4. Symptom index 
scoring: all 
necessary 
symptoms 
aggregated into a 
single summary 
score 
Not met: 20 items 
covering 10 
necessary 
symptoms 
separated into 
mutually 
independent 10 
summary scales 
Partially met: 
Total score 
includes10 items 
covering 8/10 
necessary 
symptoms but 
also includes 29 
surplus items 
Partially met: 
total score 
includes 6/10 
necessary 
symptoms plus  
2 surplus 
items 
Partially met: Total 
score includes all 10 
necessary symptoms 
plus  8 surplus items, 
including some 
treatment side-effects 
and 3 items about 
function and wellbeing 
Partially 
met: Total 
score 
includes all 
10 necessary 
symptoms 
plus 12  
surplus items 
Met: psychometric 
properties to be 
assessed in Stage 2 of 
GCIG-SBS4, along 
with the Treatment 
concerns index, 
containing 17 of the 
20 surplus items 
1. Content validity was defined as symptoms including all 10 symptoms necessary for the target population (women with symptomatic ovarian cancer) and purpose 
(to provide efficient and targeted measurement of symptom benefit for use in clinical trial endpoint analysis). The guiding principle was “everything that matters 
and no more”, so items that were not necessary to this purpose were considered surplus to it. 
2. Recall period of 3-4 weeks, matched to the typical length of a cycle of palliative chemotherapy for recurrent ovarian cancer.  
3. 3a. All but two items are rated on a 4-point Likert scale: 1 = “not at all”, 2 = “a little”, 3=”quite a bit”, 4=”very much”. The two exceptions are the global 
QOL/health items, rated on a 7-point scale, anchored at 1 “very poor” and 7 = “excellent”. 
3b. All items are rated on a 5-point verbal rating scale: 0 = “not at all”, 1 = “a little bit”, 2 = “somewhat”, 3=”quite a bit”, 4=”very much” 
3c. All items are rated on an 11-point numeric rating scale, from 0 = “did not have the symptom” to 10 = “as bad as I can imagine”. 
3d. All symptoms and treatment concerns rated on an11-point numeric rating scale, from 0 = “no trouble at all” to 10 = “worst I can imagine”, with intermediate 
verbal anchors at 2 = “mild”, 5 = “moderate” and 8 = “severe”. The three wellbeing items range from 0 = “worst possible” to 10 = “best possible”.   
4. GCIG-SBS: Gynecologic Cancer Intergroup Symptom Benefit Study 
 Table 3  Number of questions in the QLQ-C30, QLQ-OV28, FACT-O and FOSI (8 and 18 item versions) that address the 10 symptoms that are 
necessary to measure subjective symptom benefit in clinical trials of palliative chemotherapy for ovarian cancer, and number that address other 
issues (surplus items).  
 
 
QLQ-
C30 
QLQ-
OV28 
EORTC 
C30+OV28 
FACT-O FOSI 
(8) 
NCCN-
FACT 
FOSI-18 
SRQ 
The 10 necessary symptoms:        
1. Pain - general 2 - 2 1 1 1 1 
2. Abdominal bloating/discomfort - 4 4 2 2 2 1 
3. Fatigue 3 - 3 1 1 2 1 
4. Sleep disturbance 1 - 1 1 - 1 1 
5. Bowel problems 2 2 4 1 - 2 1 
6. Nausea and vomiting 2 - 2 2 2 2 1 
7. Shortness of breath 1 - 1 - - - 1 
8. Appetite 1 1 2 1 - - 1 
9. Urinary problems - 1 1 - - - 1 
10. Weight changes - - - 1 - - 1 
Number of items addressing necessary 
symptomsa 
12 8 20 10 6 10 10 
Number of surplus itemsa 18 20 38 29 2 8 12 
Number of necessary symptoms missed 2 6 0 2 6 4 0 
 
a. “Necessary items” are those that relate to the 10 symptoms that are necessary and sufficient to measure subjective symptom benefit in clinical 
trials of palliative chemotherapy for ovarian cancer. “Surplus items” are relate to other symptoms or issues. 
 
Table 4  Number of summary scales in the QLQ-C30 and QLQ-OV28, and the 
number of questions in each that address the 10 symptoms necessary to measure 
subjective symptom benefit in clinical trials of palliative chemotherapy for ovarian 
cancer.  
Type Questionnaire Summary scale, as 
specified by the 
EORTC standard 
scoring algorithms 
 Number of questions (items) 
Necessary and 
sufficient 
symptomsa 
Surplus 
symptoms / 
issues 
Symptoms QLQ-C30 Pain 2   
  Fatigue 3  
  Nausea &vomiting  2  
  Diarrhea 1  
  Constipation 1  
  Dyspnea 1  
  Appetite 1  
  Sleep 1  
  Financial concerns  1 
 QLQ-OV28 Abdominal/GI  7  
  Peripheral neuropathy  3 
  Hormonal/menopausal  2 
  Other chemo side-
effects 
1 6 
Functioning  QLQ-C30 Physical functioning  5 
  Role functioning  2 
  Social functioning  2 
  Emotional functioning  4 
  Cognitive functioning  2 
 QLQ-OV28 Body image  2 
  Sexuality  4 
  Attiude to 
disease/treatment 
 3 
Global  QLQ-C30 Global quality of 
life/health 
 2 
Total items   20 38 
Total scales   10 13 
 
Table 5 Number of multi-item scales in the FACT-G, FACT-O and FOSI (8 and 18 
item versions), and the number of items in each that address the 10 symptoms 
necessary and sufficient to measure subjective symptom benefit in clinical trials of 
palliative chemotherapy for ovarian cancer.   
Questionnaire Summary scales, as specified by 
the FACIT standard scoring 
algorithms 
Number of items 
Necessary and 
sufficient 
symptoms 
Surplus 
symptoms / 
issues 
FACT-G Physical well-being (PWB) 3 4 
 Functional well-being (FWB) 1 6 
 Emotional well-being (EWB) - 6 
 Social/family well-being (SWB) - 7 
 FACT-G total score (TOT) 
     = PWB+FWB+EWB+SWB 
4 23 
FACT-O Additional (ovarian) concerns 
(AC) 
6 6a 
 FACT-O total score = TOT+AC 10 29 
 Trial outcome index (TOI)         
     = PWB+FWB+AC 
10 16 
FOSI-8 FOSI-8 6 2b 
NFOSI-18 NFOSI-8 10 8c 
 Disease-related symptoms – 
Physical (DRS-P) 
8 1 
 Disease-related symptoms –
Emotional (DRS-E) 
- 1 
 Treatment side effects (TSE) 2 3 
 Function and wellbeing (FWB) - 3 a. The six other issues are: “I am bothered by hair loss”, “I like the appearance of my body”, “I am able to get around by myself”, I am able to feel like a woman”, “I am interested in sex”, “I have concerns about my ability to have children”.  b. The two other issues are: “I worry my condition will get worse” and “I am content with the quality of my life right now”.  c. The eight other issues are: the two additional FOSI-8 questions plus “I am bothered by skin problems”, “I am able to get around by myself”, “I am able to enjoy life”, “I feel ill”, “I am bothered by hair loss” and “I am bothered by side effects of treatment”.  
 
 

